TY - JOUR
T1 - Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
AU - van Lierop, Zoë Y. GJ
AU - Toorop, Alyssa A.
AU - van Ballegoij, Wouter J. C.
AU - Olde Dubbelink, Tom B. G.
AU - Strijbis, Eva M. M.
AU - de Jong, Brigit A.
AU - van Oosten, Bob W.
AU - Moraal, Bastiaan
AU - Teunissen, Charlotte E.
AU - Uitdehaag, Bernard M. J.
AU - Killestein, Joep
AU - Kempen, Zoé L. E. van
N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The MS Center Amsterdam is supported by a program grant (grant no. 18-358f) from the Dutch MS Research Foundation. Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Z.Y.G.J. van Lierop, A.A. Toorop, W.J.C. van Ballegoij, T.B.G. Olde Dubbelink, E.M.M. Strijbis, B.A. de Jong, B.W. van Oosten, B. Moraal, and Z.L.E. van Kempen report no disclosures relevant to the manuscript. C.E. Teunissen has served on advisory boards for Roche, has received nonfinancial support in the form of research consumables from ADx NeuroSciences and Euroimmun, and has performed contract research or received grants from Probiodrug, Biogen, Esai, Toyama, Janssen Prevention Center, Boehringer, Axon Neuroscience, EIP Pharma, PeopleBio, and Roche. B.M.J. Uitdehaag reports personal fees from Genzyme, Biogen Idec, Teva Pharmaceutical Industries, Merck Serono, and Roche. J. Killestein has accepted speaker fees from Merck Serono, Biogen, Roche, Teva Pharmaceutical Industries, Genzyme, and Novartis. Publisher Copyright: © The Author(s), 2021.
PY - 2021
Y1 - 2021
N2 - In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30–38] weeks. No clinical relapses were reported and a minority of patients showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable during extended intervals. Two (1.9%) of 107 patients with a follow-up magnetic resonance imaging (MRI) scan showed radiological disease activity. Personalized dosing of ocrelizumab could significantly extend intervals with low short-term disease activity incidence, encouraging future research on long-term safety and efficacy.
AB - In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30–38] weeks. No clinical relapses were reported and a minority of patients showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable during extended intervals. Two (1.9%) of 107 patients with a follow-up magnetic resonance imaging (MRI) scan showed radiological disease activity. Personalized dosing of ocrelizumab could significantly extend intervals with low short-term disease activity incidence, encouraging future research on long-term safety and efficacy.
KW - COVID-19
KW - Multiple sclerosis
KW - neurofilament light
KW - ocrelizumab
KW - personalized dosing
UR - http://www.scopus.com/inward/record.url?scp=85109664296&partnerID=8YFLogxK
U2 - https://doi.org/10.1177/13524585211028833
DO - https://doi.org/10.1177/13524585211028833
M3 - Article
C2 - 34240631
SN - 1352-4585
JO - Multiple sclerosis (Houndmills, Basingstoke, England)
JF - Multiple sclerosis (Houndmills, Basingstoke, England)
ER -